Improving AAV vector manufacture: a question of scale

Cell & Gene Therapy Insights 2021; 7(3), 417–426


Published: 29 April 2021
Silke Wissing, Juliana Coronel, Jens Wölfel, David Mainwaring, Amar Joshi

Silke Wissing

Chief Scientific Officer, Cevec Pharmaceuticals

Juliana Coronel

Head of Upstream Process Development, Cevec Pharmaceuticals

Jans Wölfel

Head of Downstream Processing and Analytics, Cevec Pharmaceuticals

David Mainwaring

Principal Scientist, Pall

Amar Josh

Senior Scientist, Pall

Listen to the full podcast:

Listen to each individual question and answer:

This article is part of the Viral vector bioprocessing spotlight